Relationship between elevated liver enzyme with iron overload and viral hepatitis in thalassemia major patients in Northern Iran

Mitra Ameli, MD, Sepiedeh Besharati, MD, Kourosh Nemati, MD, Farbad Zamani, MD

ABSTRACT

Objectives: To determine the relationship between elevated ALT with iron overload, transfusion index, age, and anti-HCV positivity in thalassemic patients of Tonekabon is recommended to re-evaluate transfusion and Desferal doses and therapies other than blood transfusion.

Methods: This descriptive cross-sectional study was carried out in the thalassemic ward of Tonekabon Hospital, Mazandaran, Northern Iran from 20 April to 20 September of 2006. Patients were studied with respect to age, liver enzymes, anti-hepatitis C virus (anti-HCV) antibody, and hepatitis B surface antigen (HBsAg), transferrin saturation (TSAT), and blood transfusion index (multiplication of frequency and units of transfusion). Alanine aminotransferase (ALT) ≥40U/L was considered elevated.

Result: Sixty-five patients were evaluated (median age 19.51±8.9 years, range 4-54). Eleven patients were anti-HCV positive (16.9%). The mean serum ferritin was significantly higher in patients with ALT ≥40 (2553.08 µg/L versus 1783.7750 µg/L) (p=0.012). The mean ALT was significantly higher in patients with TSAT <60% (41.26 U/L versus 28.82 U/L) (p=0.021). The relationship between ALT ≥40 and anti-HCV positivity was statistically significant. The mean ALT was 60.91 U/L in anti-HCV positive patients and 39.29 U/L in the negative group (p=0.001). The mean serum iron and transfusion index were significantly higher in anti-HCV positive versus negative patients (234.0 versus 195.4815; p=0.02), (1693.6 versus 1036.29, p=0.014).

Conclusion: Close association between elevated ALT with iron overload, transfusion index, age, and anti-HCV positivity in thalassemic patients of Tonekabon is recommended to re-evaluate transfusion and Desferal doses and therapies other than blood transfusion.
Thalassemia is a hereditary anemia resulting from defects in hemoglobin production.  

Beta-thalassemia, which is caused by a decrease in the production of beta-globin chains, affects multiple organs and is associated with considerable morbidity and mortality. The anemia that is associated with thalassemia may be severe and is accompanied by ineffective erythropoiesis, with bone expansion and extramedullary hematopoiesis in the liver, spleen, and other sites, such as paravertebral masses. Transfusion therapy, which is the mainstay of treatment, allows for normal growth and development and suppresses ineffective erythropoiesis. Iron overload results both from transfusional hemosiderosis and excess gastrointestinal iron absorption. Iron deposition in the heart, liver, and multiple endocrine glands results in severe damage to these organs, with variable endocrine organ failure. The most serious result of iron overload is life-threatening cardiotoxicity, for which chelation therapy is required. Approximately 73% of those born with thalassemia can potentially develop iron overload and toxicity from transfusions and/or increased iron absorption. In particular, beta-thalassemia major has a high mortality rate if regular red blood cell transfusions are carried out, but no chelation therapy is available. The most common and indirect methods for estimating body iron status are serum ferritin and transferrin iron saturation. Usually, serum ferritin levels >2.5 mg/l, transferrin iron saturation >100% and liver iron concentration >7 mg iron per gram liver dry weight suggest the presence of toxic levels of iron in the tissues and the need for the use of a more aggressive chelation therapy regime. Iron-chelation therapy is largely responsible for doubling the life expectancy of patients with thalassemia major. Adequate iron chelation is expensive. Therefore, alternatives to blood transfusion and chelation (such as reactivation of HbF, antioxidant agents, stem cell transplantation, gene therapy and other molecular approaches) would be valuable to increasing the safety and decrease the costs of thalassemia treatment and to provide effective treatment for patients who do not have access to blood transfusions. 

Transfusion-transmitted infections (TTI) continue to be a major challenge for blood transfusion organizations across the world. The problem is more serious in the developing countries with lower economic means. Studies demonstrated that hepatitis C virus (HCV) is the most prevalent TTI and remains a major health problem for these patients. Hepatitis C virus is a major cause of chronic hepatitis in patients with thalassemia major and is associated with raised aspartate aminotransferase (AST) activity and serum ferritin concentration compared with patients seronegative for anti-HCV. Improved survival of patients with thalassemia has given new importance to adult complications such as endocrinopathies and hepatitis that have a major impact on the quality of life. The aim of this study was to determine the relationship between elevated liver enzyme with serum iron status and HCV infection in thalassemic patients.

Methods. In a descriptive cross sectional study, 65 patients with thalassemia major ranging in age from 4-54 years and mean age ± SD of 19.51±8.9 years and who were recruited regularly to the thalassemic ward of Tonekabon Hospital, Iran from April to September of 2006 were enrolled. Patients with irregular transfusion and incompliance were excluded. The patients were given transfusions of red cells as needed to raise their hemoglobin level from 8-9 gram per deciliter to 12-14 gram per deciliter. They underwent blood transfusion minimum one and maximum 3 times a week. Each unit of blood transfused was considered to contain 4 mmol (225 mg) of iron. This study included only patients for whom there was reliable information on the use of blood products. At each patient visit, a detailed clinical and laboratory evaluation was taken. All the patients selected for the study, after being fully briefed, gave their informed consent. The project was approved by the Ethics Committee of the Faculty of Medicine, Iran University of Medical Sciences.

Serum iron status was assessed in blood samples obtained from each patient 10 days after blood transfusion to measure the serum iron, serum ferritin and transferrin saturation. Transferrin saturation was calculated as follows: (serum iron/total iron body capacity (TIBC)) x 100 and values were expressed as percentage (%). The transferrin saturation was considered elevated at values ≥60%. Alanine aminotransferase (ALT, U/L) was determined in serum samples. For comparisons, we considered values of ALT as an index based upon 40 U/L, classifying patients as normal (<40 U/L) or as elevated ALT (≥40 U/L). Anti-HCV antibody and HBsAg were detected in serum samples by a third-generation enzyme-linked immunosorbent assay. We considered transfusion index expressed as transfusion frequency times the number of red blood cell units transfused in the month. Mean ALT was compared in patients with transferrin saturation ≥60% to patients with transferrin saturation <60%, and in anti-HCV positive versus anti-HCV negative patients. Also, mean serum iron, serum ferritin, and transferrin saturation was compared with anti-HCV positives and negatives. The K2 test, the t-test, and odds ratio (OR) with 95% confidence intervals were used when appropriate. A p-value of 0.01 was considered to indicate statistical significance. The Statistical Package for Social Sciences 14.0 was used for data analysis.
**Results.** Of 65 patients, 25 (38.5%) had an elevated ALT. Approximately 27.7% had a transferrin saturation of 30-60 and 72.3% had a transferrin saturation of ≥60, and all of patients had a high normal serum ferritin. None of them was HBsAg positive, but 11 (16.9%) patients were anti-HCV positive. In comparison between normal and elevated ALT patients based on iron status parameters and anti-HCV positivity; the mean serum ferritin in elevated ALT (2553.08 µg/L) was significantly higher than with normal ALT (1783.775 µg/L) [T(63) = -2.596; \( p = 0.012 \)]. Mean ALT in patients with transferrin saturation ≥60 was significantly higher than patients with transferrin saturation 30-60. [T(47) = 2.37; \( p = 0.021 \) (Table 1)]. Nine (81.8%) of elevated ALT patients were anti-HCV positive therefore we found a significant relationship between elevated ALT and anti-HCV positivity \( [\chi^2_{(1)} = 10.86; \ p = 0.001) \] (Table 1). In comparison, between anti-HCV positive and negative patients; mean age, serum iron, and transfusion index in positive patients were significantly higher than those in negative patients \( (p = 0.025, \ p = 0.02 \) and \( p = 0.014 \)) (Table 2).

**Discussion.** We investigated the relationship between elevated liver enzyme (ALT) and iron overload and viral hepatitis in thalassemia major patients; however, a bigger sample size may detect more reliable association. We found that 27.7% of patients had TS of 30-60 and 72.3% of them had TS of ≥60 and all patients had a high normal serum ferritin. Silva et al.\(^{14}\) reported serum iron was elevated in 28%, FS in 27%, and transferrin saturation in 12.5% of patients. In our study, the mean serum ferritin in elevated ALT patients was significantly higher than those with normal ALT. Mean ALT in patients with transferrin saturation ≥60 was significantly higher than those patients with transferrin saturation 30-60. At multivariate analysis, Parti et al.\(^{15}\) showed that necroinflammation was related to the increased serum aminotransferases and higher iron stores including serum ferritin \( (p < 0.05) \). Significant fibrosis and its progression is mostly influenced by iron overload. Ruhl and Everhart\(^{16}\) study suggested that abnormal ALT levels \( (p < 0.05) \) included higher transferrin saturation and iron. Worwood et al.\(^{17}\) showed a high correlation between serum ferritin concentration and ALT activity. In our study, we found a significant relationship between elevated ALT and anti-HCV positivity. Maier et al.\(^{18}\) showed that the most common causes of elevated amino transferase levels are chronic hepatitis B and C. Wu et al.\(^{19}\) study suggested that increased ALT’s levels occurred more frequently in hepatitis C positive thalassemia major patients. Chang et al.\(^{20}\) showed that the prevalence of raised ALT and AST \( (\geq 45 \text{ IU/liter}) \) in the HCV-positive group was more significant than in the negative group. Wang et al.\(^{21}\) showed a strong positive correlation between the prevalence of an elevated ALT level and anti-HCV positivity. Wang et al.\(^{22}\) showed that subjects with elevated ALT levels were more likely to be seropositive for anti-HCV. The serum level of alanine aminotransferase was found to be significantly altered between the 2 groups of HCV-infected and non-infected thalassemic patients in Chakravarti and Verma’s\(^{23}\) study. In our study, mean age, serum iron, and

### Table 1 - Relationship between undesirable alanine aminotransferase (ALT) with ferritin, transferrin saturation, and anti-hepatitis C virus (anti-HCV).

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Normal n=40</th>
<th>Elevated n=25</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ferritin</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number</td>
<td>39</td>
<td>26</td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>1783.775</td>
<td>2553.0800</td>
<td>0.012</td>
</tr>
<tr>
<td>SD</td>
<td>10.86228</td>
<td>1262.7229</td>
<td></td>
</tr>
<tr>
<td><strong>Transferrin saturation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30-60 (%)</td>
<td>13 (72.2)</td>
<td>5 (24.8)</td>
<td>0.021</td>
</tr>
<tr>
<td>≥60 (%)</td>
<td>27 (57.4)</td>
<td>20 (42.6)</td>
<td></td>
</tr>
<tr>
<td><strong>Anti-HCV</strong></td>
<td></td>
<td></td>
<td>0.001</td>
</tr>
<tr>
<td>Positive</td>
<td>2 (18.2)</td>
<td>9 (81.8)</td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>38 (71.4)</td>
<td>16 (29.6)</td>
<td></td>
</tr>
</tbody>
</table>

### Table 2 - Relationship between anti-hepatitis C virus (anti-HCV) positivity with age, serum iron, and transfusion index.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Age (n)</th>
<th>Anti-HCV</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Positive</td>
<td>Negative</td>
<td></td>
</tr>
<tr>
<td><strong>Age (n)</strong></td>
<td>11</td>
<td>54</td>
<td>0.025</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>28.27 ± 9.634</td>
<td>17.42 ± 7.718</td>
<td></td>
</tr>
<tr>
<td><strong>Serum iron (n)</strong></td>
<td>11</td>
<td>54</td>
<td>0.02</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>234.0000 ± 49.48939</td>
<td>195.4815 ± 48.69068</td>
<td></td>
</tr>
<tr>
<td><strong>Transfusion index (n)</strong></td>
<td>11</td>
<td>54</td>
<td>0.014</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>1693.60 ± 716.357</td>
<td>1036.29 ± 7558.237</td>
<td></td>
</tr>
</tbody>
</table>
transfusion index in anti-HCV positive patients (28.27 years, 234.00µg/dl and 1693.60) were significantly higher than the negative group. Wanachiwanawin et al24 showed that there was no significant relationship between the presence of anti-HCV antibodies and the number and frequency of blood transfusions. The findings of Ocak et al25 indicated that patients who were anti-HCV positive had a significantly higher mean number of blood transfusions and peak serum alanine transaminase level than anti-HCV-negative patients. Gattoni et al26 showed that patients with elevated serum iron markers have more chronic hepatitis. The prevalence of hepatitis viruses and raised ALT levels are found to be significantly associated with the increasing age and number of blood units transfused to them that was shown in Jaiswal's et al27 study. Mirmomen et al28 in a univariate analysis showed that beta-thalassemia major (p=0.01), older age (p=0.001), longer transfusion duration (p=0.000), HBsAg seropositivity (p=0.03), and higher serum ferritin level (p=0.002) were significantly associated with a higher prevalence of HCV.

It is concluded that HCV is a major cause of chronic hepatitis in patients with thalassaemia major and is associated with raised ALT activity, serum iron concentration, and transfusion index compared with patients seronegative for anti-HCV. The findings suggest that both HCV and iron overload are the main causes of abnormal liver function in patients with thalassemia. The treatment of both problems, if coexisting in patients with thalassemia, is required to prevent progression to chronic liver disease. We recommended to reevaluate transfusion and desferal doses and therapies other than blood transfusion in these patients.

Acknowledgment. The authors wish to thank all the members of the thalassemic ward of Tonekabon Hospital and the thalassemic patients for their participation in this study.

References

18. Maier KP. [The patient with slightly increased liver function tests]. Praxis (Bern 1994) 2005; 94: 139-143, German.
Iron overload and hepatitis in thalassemia … Ameli et al


Related topics


